Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;2003(2):CD003467.
doi: 10.1002/14651858.CD003467.

Amantadine for dyskinesia in Parkinson's disease

N J Crosby  1 , K H O Deane, C E Clarke
Affiliations

Amantadine for dyskinesia in Parkinson's disease

N J Crosby et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: Abnormal involuntary movements known as dyskinesias are amongst the most disabling side-effects of levodopa therapy. It is thought that amantadine, an NMDA-receptor antagonist, may reduce dyskinesias in patients with Parkinson's disease without worsening Parkinsonian symptoms.

Objectives: To compare the efficacy and safety of adjuvant amantadine therapy versus placebo in treating dyskinesia in patients with Parkinson's disease, already established on levodopa, and suffering from motor complications.

Search strategy: Electronic searches of The Cochrane Controlled Trials Register (The Cochrane Library Issue 3, 2001), MEDLINE (1966-2001), EMBASE (1974-2001), SCISEARCH (1974-2001), BIOSIS (1993-2001), GEROLIT (1979-2001), OLDMEDLINE (1957-1965), LILACS (1982-2001), MedCarib (17th Century - 2001), PASCAL (1973-2001), JICST-EPLUS (1985-2001), RUSSMED (1973-2001), DISSERTATION ABSTRACTS (2000-2001), SIGLE (1980-2001), ISI-ISTP (1990-2001), Aslib Index to Theses (2001), Clinicaltrials.gov (2001), metaRegister of Controlled Trials (2001), NIDRR (2001) and NRR (2001) were conducted. Grey literature was hand searched and the reference lists of identified studies and reviews examined. The manufacturers of amantadine were contacted.

Selection criteria: Randomised controlled trials comparing amantadine with placebo in the treatment of dyskinesia in patients with a clinical diagnosis of idiopathic Parkinson's disease.

Data collection and analysis: Data was abstracted independently by NC and KD onto standardised forms and disagreements were resolved by discussion.

Main results: Three randomised controlled trials were found comparing amantadine with placebo in the treatment of dyskinesia in patients with idiopathic Parkinson's disease. Three trials were excluded on the basis that they had no control group and a further three did not state whether they randomised the treatment that participants received. The included trials were double-blind cross-over studies involving a total of 53 patients. All three studies failed to present data from the first arm, instead presenting results as combined data from both treatment arms and both placebo arms. Two trials had no wash-out interval between the treatment periods. In view of the risk of a carry-over effect into the second arm, the results of these trials were not analysed. The final trial had a one week wash-out interval but only examined 11 participants. One study reported side-effects of amantadine in 8 of the 18 participants, including confusion and worsening of hallucinations. Another reported reversible edema of both feet in one of eleven participants.

Reviewer's conclusions: Due to lack of evidence it is impossible to determine whether amantadine is a safe and effective form of treatment for levodopa-induced dyskinesias in patients with Parkinson's disease.

PubMed Disclaimer

Conflict of interest statement

None.

References

References to studies included in this review

Luginger 2000 {published data only}
    1. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease. Movement Disorders 2000;15(5):873‐878. - PubMed
Snow 2000 {published data only}
    1. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa‐induced dyskinesias in Parkinson's disease: A double‐blind, placebo‐controlled study. Clinical Neuropharmacology 2000;23(2):82‐85. - PubMed
Verhagen Metman 1998 {published data only}
    1. Verhagen L, Dotto MP, Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease [Amantadin zur behandlung von dyskinesien und motorischen fluktuationen beim morbus parkinson]. Nervenheilkunde 1998;17(10):480‐484.
    1. Verhagen Metman L, Dotto P, Blanchet PJ, Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 1998;14(1‐3):75‐82. - PubMed
    1. Verhagen Metman L, Dotto P, Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50(5):1323‐1326. - PubMed

References to studies excluded from this review

Cersosimo 2000 {published data only}
    1. Cersosimo MG, Scorticati MC, Micheli FE. Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease. Medicina (B Aires) 2000;60(3):321‐325. - PubMed
Del Dotto 2001 {published data only}
    1. Dotto P, N Pavese, G Gambaccini, S Bernardini, L Vergagen Metman, T N Chase, U Bonuccelli. Intravenous amantadine improves levodopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study. Movement Disorders 2001;3:515‐520. - PubMed
Kim 2000 {published data only}
    1. Kim JW, Jung JI. The amantadine treatment for levodopa induced dyskinesia in Parkinson's disease. Movement Disorders 2000;15 (Suppl. 3):108.
Rajput 1997 {published data only}
    1. Rajput AH, Uitti RJ, Lang AE, Rajput AH, Kumar R, Galvez‐Jimenez N. Amantadine ameliorates levodopa induced dyskinesia. Neurology 1997;48:A328.
Rajput 1998 {published data only}
    1. Rajput AH, Rajput A, Lang AE, Kumar R, Uini RJ, Galvez‐Jimenez N. New use for an old drug: Amantadine benefits levodopa‐induced dyskinesia. Movement Disorders 1998;13(5):851. - PubMed
Ruzicka 2000 {published data only}
    1. Ruzicka E, Streitova H, Jech R, Kanovsky P, Roth J, Rektorova I, Mecir P, Hortova H, Bares M, Hejdukova B, Rektor I. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. Journal of Neural Transmission 2000;107(11):1297‐1306. - PubMed
Verhagen 1999 {published data only}
    1. Verhagen L, Dotto P, LePoole K, Konitsiotis S Fang J, Gillespie M, Chase T. Amantadine for levodopa‐induced dyskinesias. XIII International Congress on Parkinson's Disease. Vancouver, Canada, 1999.
Verhagen Metman1998 {published data only}
    1. Verhagen Metman L, Dotto P, Munckhof P, Fang J, Mouradian MM, Chase TN. [Amantadin zur behandlung von dyskinesien und motorischen fluktuationen beim morbus Parkinson]. Nevenheilkunde 1998;17:480‐484.
Verhagen Metman1999 {published data only}
    1. Verhagen L, Dotto P, LePoole K, Konitsiotis S, Fang J, Gillespie M, Chase T. Amantadine for levodopa‐induced dyskinesias. XIIIth International Congress on PD 1999;5.
    1. Verhagen Metman L, Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa‐induced dyskinesias [Amantadin bei levodopa‐induzierten dyskinesien: eine 1‐jahres‐ kontrollstudie]. Nervenheilkunde 2000;19(5):276‐279.
    1. Verhagen Metman L, Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa‐induced dyskinesias: A 1‐year follow‐up study. Archives of Neurology 1999;56(11):1383‐1386. - PubMed

Additional references

Chase 1996
    1. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Advances in Neurology 1996;69:497‐501. - PubMed
CONSORT 2001
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomised trials. The Lancet 2001;357:1191‐1194. - PubMed
Crosby 2002
    1. Crosby N, Deane KHO, Clarke CE. Amantadine in Parkinson's disease (Cochrane review). The Cochrane Library 2002, Issue 2. - PMC - PubMed
Engber 1994
    1. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586‐2588. - PubMed
Hughes 1992
    1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico‐pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 1992;3:181‐184. - PMC - PubMed
Kornhuber 1994
    1. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. Journal of Neural Transmission 1994;43:91‐104. - PubMed
Marconi 1994
    1. Marconi R, D Lefebvre‐Caparros, A‐M Bonnet, M Vidailhet, B Dubois, Y Agid. Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Movement Disorders 1994;9(1):2‐12. - PubMed
Papa 1996
    1. Papa SM, Chase TN. Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Annals of Neurology 1996;39:574‐578. - PubMed
Pechevis 2001
    1. Pechevis M, Clarke CE, Vieregge P, Ziegler M, Berdeaux G, Barland JC, Gardner J. Direct and indirect costs of Parkinson's disease (PD) and L‐dopa‐induced dyskinesia: a prospective European study. Parkinsonism and Related Disorders. 2001; Vol. 7:S106.
Quinn 1986
    1. Quinn N, Critchley P, Parkes D, Marsden CD. When should levodopa be started?. Lancet 1986;ii:986‐986. - PubMed
Rajput 1984
    1. Rajput AH, Stern W, Laverty WH. Chronic low‐dose levodopa therapy in Parkinson's disease. Neurology 1984;34:991‐996. - PubMed

Publication types

MeSH terms